secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001193125-26-100131
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva reports FY2025 net loss of $83.9M; cash $108M into Q2 2027
-----------------------------------------------------------------

- Net loss $83.9M vs $65.4M in 2024; R&D spend $69.5M (up 38% YoY); revenue zero.
- Cash, equivalents and investments $108.0M as of Dec 31, 2025, expected to fund operations into Q2 2027.
- AlloNK for refractory RA: initial clinical response data from ≥15 patients expected H1 2026; FDA Fast Track granted.
- Planned FDA interaction in H1 2026 to discuss potential pivotal trial design for AlloNK in refractory RA.
- Appointed Subhashis Banerjee, M.D. as CMO and Thad Huston as CFO; added two board members with immunology/commercial expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526100131/0001193125-26-100131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526100131/artv-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-100131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer